Therapeutic implications of new insights into the critical role of VP16 in initiating the earliest stages of HSV reactivation from latency

Herpes Simplex Virus Type 1 in Alzheimer's Disease: The Enemy Within

(2017) Ruth F. Itzhaki et al.   JOURNAL OF ALZHEIMERS DISEASE

Clinical and Virologic Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial

(2010) Jonathan Fuchs et al.   JOURNAL OF INFECTIOUS DISEASES

Persistence of HIV-1 receptor–positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition

(2009) Jia Zhu et al.   NATURE MEDICINE

Inhibition of the histone demethylase LSD1 blocks α-herpesvirus lytic replication and reactivation from latency

(2009) Yu Liang et al.   NATURE MEDICINE

De Novo Synthesis of VP16 Coordinates the Exit from HSV Latency In Vivo

(2009) Richard L. Thompson et al.   PLoS Pathogens

Drug-induced crystal nephropathy: an update

(2008) Sri G Yarlagadda et al.   Expert Opinion On Drug Safety

Chromatin control of herpes simplex virus lytic and latent infection

(2008) David M. Knipe et al.   NATURE REVIEWS MICROBIOLOGY

Noncytotoxic Lytic Granule-Mediated CD8+ T Cell Inhibition of HSV-1 Reactivation from Neuronal Latency

(2008) J. E. Knickelbein et al.   SCIENCE